ライフサイエンスコーパス: obstructive sleep apnoea

1 re (NCPAP) is widely used as a treatment for obstructive sleep apnoea.

2 d with pathological conditions, particularly obstructive sleep apnoea.

3 eflex is associated with sleep disruption in obstructive sleep apnoea.

4 to consider treatment for patients with mild obstructive sleep apnoea.

5 sitive airway pressure in patients with mild obstructive sleep apnoea.

6 ed the quality of life in patients with mild obstructive sleep apnoea.

7 the arousal threshold, in participants with obstructive sleep apnoea.

8 leaders to estimate the global prevalence of obstructive sleep apnoea.

9 continuous positive airway pressure-treated obstructive sleep apnoea.

10 which are rarely developed specifically for obstructive sleep apnoea.

11 lar mechanism for elevated blood pressure in obstructive sleep apnoea.

12 incident T2DM, hypertension, angina, MI, and obstructive sleep apnoea.

13 na, Spain, for abnormal sleep behaviours and obstructive sleep apnoea.

14 the metabolic syndrome, type 2 diabetes, and obstructive sleep apnoea.

15 ics for upper airway motor disorders such as obstructive sleep apnoea.

16 d in sudden infant death syndrome (SIDS) and obstructive sleep apnoea.

17 reflex function is impaired in patients with obstructive sleep apnoea.

18 e to promoting hypertension in patients with obstructive sleep apnoea.

19 ly to the major clinical problem of cyclical obstructive sleep apnoea.

20 provide a mechanism linking hypertension to obstructive sleep apnoea.

21 k of cardiovascular disease in patients with obstructive sleep apnoea.

22 0.40-0.87);MI, 0.28 (95% CI 0.10-0.74); and obstructive sleep apnoea, 0.55 (95% CI 0.40-0.87).

23 f published data on the global prevalence of obstructive sleep apnoea, a disorder associated with maj

24 Obstructive sleep apnoea, a syndrome that leads to recur

25 Prevalence estimates for obstructive sleep apnoea across studies using different

26 The assessment of how obstructive sleep apnoea affects cognition depends on th

27 ine (AASM) 2012 scoring criteria to identify obstructive sleep apnoea, allowing determination of an e

28 69 years (men and women) have mild to severe obstructive sleep apnoea and 425 million (399-450) adult

29 predictors of negative genetic testing were obstructive sleep apnoea and a normal 12-lead ECG (both

30 ronic obstructive pulmonary disease, asthma, obstructive sleep apnoea and acute lung injury.

31 ibitors are currently in clinical trials for obstructive sleep apnoea and atrial fibrillation(16).

32 hronic hypoxia as a consequence of increased obstructive sleep apnoea and cardiovascular disease.

33 active at rest, e.g. essential hypertension, obstructive sleep apnoea and heart failure.

34 erythrocytosis and gynaecomastia, worsening obstructive sleep apnoea and increasing cardiovascular m

35 of hypertension, but the association between obstructive sleep apnoea and myocardial infarction, stro

36 review, we focus on the association between obstructive sleep apnoea and stroke reviewing both the e

37 herent complexity of the association between obstructive sleep apnoea and the brain.

38 Obstructive sleep apnoea and type 2 diabetes are common

39 ocardial infarction (MI), stroke, fractures, obstructive sleep apnoea, and cancer; mortality; and res

40 being hypertension, chronic kidney disease, obstructive sleep apnoea, and metabolic disease includin

41 s with Acute Coronary Syndrome and Nonsleepy Obstructive Sleep Apnoea, and Sleep Apnoea Cardiovascula

42 n have atypical phenotypes including ptosis, obstructive sleep apnoea, and the occurrence of seizures

43 ating many sleep-related disorders including obstructive sleep apnoea (apnea), REM sleep behaviour di

44 Male participants with obstructive sleep apnoea (apnoea-hypopnoea index > 5 eve

45 atients (>=18 years to <=80 years) with mild obstructive sleep apnoea (apnoea-hypopnoea index [AHI] >

46 abnormal sleep movements and behaviours and obstructive sleep apnoea, as confirmed by polysomnograph

47 The primary outcome was prevalence of obstructive sleep apnoea based on AASM 2012 diagnostic c

48 ublished studies reporting the prevalence of obstructive sleep apnoea based on objective testing meth

49 ea during the acute phase after stroke, with obstructive sleep apnoea being the most common subtype.

50 Obstructive sleep apnoea can be diagnosed on the basis o

51 Obstructive sleep apnoea causes sleepiness, road traffic

52 HIV and some common sleep disorders, such as obstructive sleep apnoea, chronic insomnia, and circadia

53 tive parallel trial of therapeutic NCPAP for obstructive sleep apnoea compared with a control group o

54 s that can cause brain hypoperfusion such as obstructive sleep apnoea, congestive heart failure, card

55 ittent hypercapnic hypoxia characteristic of obstructive sleep apnoea could promote hypertension by i

56 nt for metabolic abnormalities in those with obstructive sleep apnoea could reduce cardiovascular dis

57 As will be discussed, management of obstructive sleep apnoea could soon transition from a so

58 Men with obstructive sleep apnoea, defined as an Epworth sleepine

59 on-to-treat population of patients with mild obstructive sleep apnoea diagnosed using the American Ac

60 Dips suggestive of obstructive sleep apnoea did not predict CNS events, and

61 are change in blood pressure in 118 men with obstructive sleep apnoea (Epworth score > 9, and a > 4%

62 Patients with obstructive sleep apnoea experience chronic intermittent

63 lts aged 30-69 years have moderate to severe obstructive sleep apnoea globally.

64 ardiovascular related pathologies, including obstructive sleep apnoea, heart failure and diabetes.

65 Obstructive sleep apnoea-hypopnoea syndrome (OSAHS) (HR=

66 Obstructive sleep apnoea/hypopnoea syndrome, depression

67 exhibit greater improvements in severity of obstructive sleep apnoea (i.e. reduction in event freque

68 ioglossal activity observed in patients with obstructive sleep apnoea (i.e. reflex compensation for a

69 rway Pressure in Coronary Artery Disease and Obstructive Sleep Apnoea, Impact of Continuous Positive

70 Early identification of obstructive sleep apnoea in patients with metabolic dysf

71 9.37), hypothyroidism (IRR 7.22, 6.62-7.88), obstructive sleep apnoea (IRR 4.45, 3.72-5.31), and haem

72 Obstructive sleep apnoea is a common disease that is now

73 Obstructive sleep apnoea is a disease of increasing impo

74 Obstructive sleep apnoea is an increasingly common disor

75 Obstructive sleep apnoea is associated with raised blood

76 The evidence base for the treatment of mild obstructive sleep apnoea is limited and definitions of d

77 e shown that primary sleep disorders such as obstructive sleep apnoea may worsen epilepsy and treatme

78 obesity hypoventilation syndrome and severe obstructive sleep apnoea, non-invasive ventilation and c

79 re dips per h of more than 4% SaO2 caused by obstructive sleep apnoea on overnight sleep study, were

80 Two most prevalent sleep disorders, namely obstructive sleep apnoea (OSA) (BPAD 50.8.0% vs RDD 29.3

81 Obstructive sleep apnoea (OSA) and type 2 diabetes frequ

82 ed a small group of elderly individuals with obstructive sleep apnoea (OSA) for comparison (n = 3, ag

83 ositive airway pressure (CPAP) treatment for obstructive sleep apnoea (OSA) in patients with cardiova

84 Obstructive sleep apnoea (OSA) is a heterogeneous and co

85 Obstructive Sleep Apnoea (OSA) is associated with the de

86 Obstructive sleep apnoea (OSA) is characterised by inter

87 administration of oral appliance therapy for obstructive sleep apnoea (OSA) is that therapeutic respo

88 etermine whether PA and vLTF are enhanced in obstructive sleep apnoea (OSA) participants compared to

89 threshold is one of the main contributors to obstructive sleep apnoea (OSA) pathogenesis.

90 *Some patients with obstructive sleep apnoea (OSA) respond well to oral appl

91 irway pressure (CPAP) for moderate to severe obstructive sleep apnoea (OSA) syndrome have been establ

92 Obstructive sleep apnoea (OSA), characterized by recurre

93 mulating blood O2 saturation profiles during obstructive sleep apnoea (OSA), have been shown to exhib

94 mulating blood O2 saturation profiles during obstructive sleep apnoea (OSA), have been shown to exhib

95 eep fragmentation (SF), a primary feature of obstructive sleep apnoea (OSA), impairs hippocampal long

96 ttent hypoxia is a hallmark manifestation of obstructive sleep apnoea (OSA), which is a widespread re

97 Obstructive sleep apnoea (OSA), which is characterized b

98 wn to reduce loop gain (LG) in patients with obstructive sleep apnoea (OSA), yet its effects on the o

99 t to recurrent brief hypoxic episodes during obstructive sleep apnoea (OSA).

100 us responsiveness in people with and without obstructive sleep apnoea (OSA).

101 ndylosis as a risk factor for development of obstructive sleep apnoea (OSA).

102 EEG) between patients with SS and those with obstructive sleep apnoea (OSA).

103 ociated with a relatively high prevalence of obstructive sleep apnoea (OSA).

104 ociated with a relatively high prevalence of obstructive sleep apnoea (OSA).

105 reathing on return to sleep in patients with obstructive sleep apnoea (OSA).

106 ce to suggest that acetazolamide may improve obstructive sleep apnoea (OSA).However, how acetazolamid

107 g erectile dysfunction, atrial fibrillation, obstructive sleep apnoea, osteoporosis and venous thromb

108 buting to increased risk for hypertension in obstructive sleep apnoea patients.

109 Countries without obstructive sleep apnoea prevalence data were matched to

110 airway pressure, the treatment of choice for obstructive sleep apnoea, reduces sleepiness and improve

111 ive daytime sleepiness, circadian disorders, obstructive sleep apnoea, restless legs syndrome, and ra

112 The increased awareness of obstructive sleep apnoea's (OSA) links to Alzheimer's di

113 ts, video polysomnography showed features of obstructive sleep apnoea, stridor, and abnormal sleep ar

114 cles are important in the pathophysiology of obstructive sleep apnoea syndrome (OSA).

115 clearly important in the pathophysiology of obstructive sleep apnoea syndrome (OSA).

116 The contribution of genetic factors to obstructive sleep apnoea syndrome (OSAS) has led to a be

117 Repetitive hypoxia seen in obstructive sleep apnoea syndrome (OSAS) may affect bone

118 etabolism, nonalcoholic fatty liver disease, obstructive sleep apnoea syndrome, erectile dysfunction,

119 are clearly important in the pathogenesis of obstructive sleep apnoea syndrome.

120 done in the past two decades indicates that obstructive sleep apnoea, through the effects of intermi

121 233 had mild obstructive sleep apnoea using AASM 2012 criteria and we

122 nic rhinosinusitis, gastroesophageal reflux, obstructive sleep apnoea, vocal cord dysfunction, obesit

123 relates to the pathogenesis and treatment of obstructive sleep apnoea, we have developed a novel appl

124 Reliable prevalence data for obstructive sleep apnoea were available for 16 countries

125 the most recent insights and discoveries in obstructive sleep apnoea, with a focus on diagnostics an

126 e first study to report global prevalence of obstructive sleep apnoea; with almost 1 billion people a